BD FACSAria II for NJMS Flow Cytometry Core

用于 NJMS 流式细胞术核心的 BD FACSAria II

• 批准号: 8052153
• 负责人: PATRICIA FITZGERALD-BOCARSLY
• 金额: $ 50.08万
• 依托单位: UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-01 至 2012-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8052153
• 关键词: 11 year old; Advisory Committees; Aerosols; Applications Grants; Area; Biological; Biology; Cardiovascular system; Cell Count; Cell Line; Cells; Cellular biology; Commit; Communities; Contract Services; Deposition; Fees; Flow Cytometry; Funding; Grant; HIV; Housing; Human; Immunology; Infectious Disease Immunology; Institutes; Laboratories; Lasers; Life; Lupus; Minor; National Institute of Allergy and Infectious Disease; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; National Institute of Mental Health; Natural Immunity; New Jersey; Parasites; Productivity; Radiobiology; Recruitment Activity; Refrigeration; Request for Applications; Research; Research Personnel; Safety; Sampling; Science; Slide; Sorting - Cell Movement; Structure; Technology; Temperature; Time; United States National Institutes of Health; Universities; Work; cancer cell; cost; cytokine; experience; instrument; instrumentation; interest; medical schools; meetings; pathogen; stem cell biology

DESCRIPTION (provided by applicant): This Shared Instrumentation Grant (SIG) application requests funds for the purchase of a state-of-the-art Becton-Dickinson FACSAria II cell sorter to be located in the Flow Cytometry Core Laboratory at the New Jersey Medical School. The FACSAria II cell sorter has numerous advantages over the 11 year-old, technologically outdated FACSVantage it will replace. Most importantly, the FACSAria II is a compact, desk- top sorter that can be placed in a Baker BioPROTect III class II biological safety cabinet, which is also requested in this proposal. The FACSAria II will be equipped with the aerosol management option for added operator protection. These features are essential to the majority of our users who need to sort either live human cells and cell lines or live, pathogen-infected cells, including HIV-infected cells; these projects cannot currently be carried out using the FACSVantage, which lacks these safety features. Additional features of the instrument that are necessary for our SIG investigators include four-way sorting, four lasers (355 nm (UV), 488 nm, 561nm and 640 nm) with the capability of detecting up to 14 parameters, a temperature control option for refrigeration and cooling of the pre- and post-sort samples, and an automatic cell deposition unit for desposition of fixed numbers of cells into plates or onto slides. The FACSAria has additional advantages over the FACSVantage that will benefit all of our users: it is faster and more efficient and its housing in the BioPROtect III will facilitate aseptic sorts. This application is supported by projects submitted by 10 major users and 9 minor users; the lasers and accessories were chosen to meet the sorting needs of this very diverse group of investigators. While a number of the investigators work in the area of infectious disease immunology, including, e.g., HIV immunology, parasite immunology, innate immunity, and cytokines, other investigators work in diverse areas such as cancer cell biology, stem cell biology, radiation biology, cardiovascular biology and lupus. This diversity in research interests is reflected in the fact that these SIG investigators are funded by six different institutes at the NIH: the NIAID, NCI, NIGMS, NIDDK, NHBLI and NIMH. All of these investigators extensively use flow cytometry in their studies, and nearly all have significant experience with sorting. There is strong institutional commitment to this FACSAria application: the medical school has committed ongoing funds for a full-time operator and service contract for the instrument. These costs will be offset, in part, by users fees from the SIG investigators and other investigators recruited to utilize this powerful technology. The FACSAria will be supported by a strong administrative structure including oversight by the Flow Cytometry Core Advisory Committee, which is chaired by the SIG PI, Dr. Fitzgerald-Bocarsly, who is also the Scientific Director of the Flow Cytometry and Immunology Core Laboratory. Overall, the introduction of this FACSAria II to our university community is expected to greatly enhance our investigators' productivity and contribution to biomedical science.

描述（由申请人提供）：本共享仪器补助金（SIG）申请要求提供资金，用于购买位于新泽西医学院流式细胞术核心实验室的最先进的Becton-Dickinson FACSAria II细胞分选仪。FACSAria II细胞分选仪与其将要取代的已有11年历史、技术过时的FACSVantage相比具有许多优势。最重要的是，FACSAria II是一种紧凑型台式分拣机，可放置在Baker BioPROTect III II类生物安全柜中，这也是本提案中要求的。FACSAria II将配备气溶胶管理选项，以增加对操作员的保护。这些功能对于我们的大多数用户来说是必不可少的，他们需要对活的人类细胞和细胞系或活的病原体感染的细胞（包括HIV感染的细胞）进行分类;这些项目目前无法使用缺乏这些安全功能的FACSVantage进行。该仪器的其他功能是必要的，我们的SIG调查人员包括四路排序，四个激光器，（355 nm（UV）、488 nm、561 nm和640 nm），能够检测多达14个参数，温度控制选项用于分拣前和分拣后样品的冷藏和冷却，以及用于将固定数量的细胞沉积到板中或载玻片上的自动细胞沉积单元。与FACSVantage相比，FACSAria具有其他优势，这将使我们所有的用户受益：它更快，更有效，其在BioPROtect III中的外壳将有助于无菌分类。这一应用得到了10个主要用户和9个次要用户提交的项目的支持;激光器和配件的选择是为了满足这一非常多样化的研究人员群体的分拣需求。虽然许多研究人员在传染病免疫学领域工作，包括，例如，艾滋病毒免疫学，寄生虫免疫学，先天免疫和细胞因子，其他研究人员在不同领域工作，如癌细胞生物学，干细胞生物学，辐射生物学，心血管生物学和狼疮。研究兴趣的多样性反映在以下事实中：这些SIG研究人员由NIH的六个不同研究所资助：NIAID，NCI，NIGMS，NIDDK，NHBLI和NIMH。所有这些研究人员都在研究中广泛使用流式细胞术，并且几乎所有人都拥有丰富的分选经验。有强大的机构承诺，这FACSAria应用：医学院已承诺为全职操作员和服务合同的仪器持续的资金。这些费用将部分由特别调查组调查员和为利用这一强大技术而征聘的其他调查员的使用费抵消。FACSAria将得到强有力的行政结构的支持，包括流式细胞术核心咨询委员会的监督，该委员会由SIG PI Fitzgerald-Bocarsly博士担任主席，他也是流式细胞术和免疫学核心实验室的科学总监。总的来说，将FACSAria II引入我们的大学社区有望大大提高我们研究人员的生产力和对生物医学科学的贡献。

项目成果

A transmissible γδ intraepithelial lymphocyte hyperproliferative phenotype is associated with the intestinal microbiota and confers protection against acute infection.

• DOI: 10.1038/s41385-022-00522-x
• 发表时间: 2022-04
• 期刊: MUCOSAL IMMUNOLOGY
• 影响因子: 8
• 作者: Jia, Luo;Wu, Guojun;Alonso, Sara;Zhao, Cuiping;Lemenze, Alexander;Lam, Yan Y.;Zhao, Liping;Edelblum, Karen L.
• 通讯作者: Edelblum, Karen L.

γδ Intraepithelial Lymphocytes Facilitate Pathological Epithelial Cell Shedding Via CD103-Mediated Granzyme Release.

• DOI: 10.1053/j.gastro.2021.11.028
• 发表时间: 2022-03
• 期刊: Gastroenterology
• 影响因子: 29.4
• 作者: Hu MD;Golovchenko NB;Burns GL;Nair PM;Kelly TJ 4th;Agos J;Irani MZ;Soh WS;Zeglinski MR;Lemenze A;Bonder EM;Sandrock I;Prinz I;Granville DJ;Keely S;Watson AJM;Edelblum KL
• 通讯作者: Edelblum KL